Pheast Therapeutics

Pheast is a pre-clinical stage immuno-oncology company focused on targeting cancer immune evasion pathways to activate the innate immune system in the fight against cancer. 

Roy Maute
Biotech

Pheast’s CEO has no regrets despite competitors gaining an edge

Pheast learned the hard way about the risks of competitors glimpsing your discoveries, but the startup's CEO told Fierce he's sticking to transparency
Will Maddox Aug 21, 2026 8:00am
Italy parachute alps mountain paraglide

NIH leaders join health agency exodus—Chutes & Ladders

Feb 21, 2025 8:30am
Parachute

New year, new C-suite execs—Chutes & Ladders

Jan 6, 2023 9:30am
graphic of a man with money identifying new ideas

Arch raises nearly $3B amid cratering biotech market

Jun 29, 2022 11:15am
Role of hundred dollar bills on other bills

Catalio reloads with $381M after financing Octant, Pheast

May 4, 2022 9:21am